Corcept Therapeutics Inc
F:HTD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Corcept Therapeutics Inc (HTD) under the Base Case is 81.56 EUR per share.
Compared with the current market price of 66.58 EUR, the stock appears
Undervalued by 18% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Corcept Therapeutics Does
Corcept Therapeutics is a specialty drug company focused on medicines that block the effects of cortisol, a hormone the body makes naturally. Its main commercial product is Korlym, a prescription drug used to treat certain patients with endogenous Cushing’s syndrome, a serious disorder caused by too much cortisol. The company also develops related cortisol-modulating drugs for other medical uses.
- Headquarters
- United States of America US
- Employees
- 730
- IPO date
- Apr 15, 2004
Corcept Therapeutics has a wide economic moat
Patents covering relacorilant and its use in ovarian cancer make it harder for rivals to copy Corcept’s approved Lifyorli treatment. FDA approval lets Corcept sell it for a defined group of patients, giving the company a protected treatment option in that market.
Read the full moat analysis
Revenue & Expenses Breakdown
Corcept Therapeutics Inc
Earnings Waterfall
Corcept Therapeutics Inc
What is the Intrinsic Value of one HTD stock?
The intrinsic value for Corcept Therapeutics Inc (HTD) under the Base Case is 81.56 EUR.
Is HTD stock undervalued or overvalued?
Compared with the current market price of 66.58 EUR, the stock appears Undervalued by 18% .
